GRAVITAS Trial Shows That a Uniform Treatment Strategy of Doubling the Standard Dose of Plavix Does Not Improve Outcomes Post-PCI

By Accumetrics Inc., PRNE
Monday, November 15, 2010

Higher Cardiac Event Rates Seen in Patients with Higher Residual Platelet Reactivity, as Measured by the VerifyNow P2Y12 Test

SAN DIEGO, November 16, 2010 - Accumetrics, Inc., developer and marketer of the VerifyNow(R) System,
today announced that the GRAVITAS (Gauging Responsiveness With A VerifyNow
Assay-Impact On Thrombosis And Safety) Trial found that in patients with high
residual platelet reactivity, doubling the maintenance dose of clopidogrel
did not reduce the risk of further ischemic events after percutaneous
coronary intervention (PCI). The study also reported that patients with high
residual platelet reactivity, as measured by the VerifyNow P2Y12 test,
demonstrated almost twice the risk of ischemic events compared to patients
without high residual platelet reactivity. The VerifyNow P2Y12 Test is used
to measure the antiplatelet effect of medications such as clopidogrel or
prasugrel (Plavix(R) and Effient(R)) that reduce platelet reactivity by
blocking the platelet P2Y12 receptor.

Matthew J. Price, MD, of the Scripps Translational Science Institute and
Scripps Clinic in La Jolla, CA, and Principal Investigator of the GRAVITAS
trial, presented the results during the American Heart Association Scientific
Sessions Late-Breaking Clinical Trials in Chicago. "The GRAVITAS findings do
not support a uniform treatment strategy of high dose clopidogrel in patients
with high residual platelet reactivity based upon a single platelet function
test after stent implantation. This is important as currently many physicians
utilize a strategy of doubling the dose of clopidogrel the morning after the
stent procedure," commented Dr. Price. "Alternative therapies or testing a
patient multiple times to treat to a specific target of reactivity deserve

"The GRAVITAS trial provides further evidence of the association between
high residual platelet reactivity, sometimes referred to as
non-responsiveness, and the occurrence of cardiovascular events. The trial
demonstrated a strong trend towards greater risk of ischemic events in
non-responders, which is consistent with prior reports," commented Jeffrey R.
, PhD, Vice President of Clinical and Regulatory Affairs for
Accumetrics. "As we further analyze the data, we expect to release additional
information that continues to support the value of platelet function

"GRAVITAS continues to position Accumetrics as a diagnostic leader that
invests in furthering clinical understanding of individualized treatment for
cardiovascular patients," said Timothy I. Still, President and CEO of
Accumetrics. "This trial highlights the importance of continually assessing
response to antiplatelet therapy as physicians consider various treatment

The VerifyNow System is the first rapid and easy-to-use point-of-care
system for measuring platelet reactivity to multiple antiplatelet agents. The
System is widely used in various clinical settings where antiplatelet
medications are prescribed to reduce the occurrence of future thrombotic
events such as heart attack and stroke. Clopidogrel is an oral antiplatelet
agent sold under the brand name Plavix.

About the GRAVITAS Study

The concept of variability in response to antiplatelet therapy has been
well established. Also being demonstrated with increased frequency is that
high residual platelet reactivity is associated with poor patient outcomes.
Accumetrics recognized the need for a study specifically designed to explore
possible treatment strategies for those patients who are poor responders to
antiplatelet therapy. As a result, the GRAVITAS study is the first
multi-center, placebo-controlled study to determine whether high maintenance
dose of clopidogrel therapy based on the results of the company's VerifyNow
P2Y12 Test reduces ischemic events post- PCI. The trial was coordinated by
Scripps Advanced Clinical Trials.

About Accumetrics

Accumetrics is committed to advancing medical understanding of platelet
function and enhancing quality of care for patients receiving antiplatelet
therapies by providing industry- leading and widely accessible diagnostic
tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy-to-use platform
to help physicians determine an individual's response to multiple
antiplatelet agents. Addressing every major antiplatelet drug, including
FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel
(Effient(R)) and clopidogrel (Plavix(R))), and GP IIb/IIIa inhibitors (e.g.
ReoPro(R) and Integrilin(R)), the VerifyNow System provides valuable
information to help physicians make informed treatment decisions. For more
information about the Company and its products, visit

The Accumetrics logo and VerifyNow are registered trademarks of
Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc.
Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is
a registered trademark of sanofi-aventis. Effient is a registered trademark
of Eli Lilly and Company.

    Megan Rusnack
    Lippert/Heilshorn & Associates

    Timothy I. Still
    President and CEO Accumetrics

Megan Rusnack of Lippert/Heilshorn & Associates, +1-212-838-3777, mrusnack at, for Accumetrics; or Timothy I. Still, President and CEO of Accumetrics, +1-858-404-8260, press at

will not be displayed